Focus: Ascentage Pharma is a China-based oncology-focused pharmaceutical company specializing in small molecule cancer therapeutics with a diversified portfolio of generic and branded products.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Ascentage Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Ascentage Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Ascentage Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Flagship product driving 90% of company revenue; exclusivity cliff in 6+ years creates urgent need for pipeline de-risking.
Early-stage ophthalmic launch; modest revenue contribution but non-oncology diversification.
Post-LOE generic facing generic competition; mature legacy product with limited growth.
Post-LOE CNS product; stable niche revenue but not a growth driver.
Mature generic electrolyte supplement with limited differentiation.
Duplicate listing of KLOR-CON generic formulation; declining revenue reflects mature market.
Duplicate entry; mature post-LOE generic with limited revenue growth potential.
NDA-type formulation with approaching LOE; consolidation of KLOR-CON franchise indicates mature legacy position.
Generic NSAID in mature market with no competitive advantage.
Generic SSRI with minimal revenue; psychiatry portfolio contributes marginally to topline.
62 discontinued, 106 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
+33 more products
+2 more
+2 more
+2 more
+2 more
+1 more
+2 more